Notably, EVH maintained a 100% logo renewal rate for top customers, representing more than 90% of revenue in 2024, including an important contract extension with Centene. The company’s 2025 ...

Truist analyst Jailendra Singh lowered the firm’s price target on Evolent Health (EVH) to $14 from $15 and keeps a Buy rating on the shares as ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.

In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on Evolent Health (EVH – Research Report). The company’s shares closed yesterday at $10.07.